<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ABBOTT LABORATORIES' 1998 FIRST QUARTER FORM 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <RESTATED> <MULTIPLIER> 1,000 <PERIOD-TYPE> 3-MOS 6-MOS 9-MOS YEAR <FISCAL-YEAR-END> DEC-31-1996 DEC-31-1996 DEC-31-1996 DEC-31-1995 <PERIOD-START> JAN-01-1996 JAN-01-1996 JAN-01-1996 JAN-01-1995 <PERIOD-END> MAR-31-1996 JUN-30-1996 SEP-30-1996 DEC-31-1995 <CASH> 87,922 111,482 139,896 281,197 <SECURITIES> 44,035 66,189 39,274 34,500 <RECEIVABLES> 1,718,488 1,791,459 1,700,153 1,721,028 <ALLOWANCES> 156,167 147,550 150,415 157,990 <INVENTORY> 1,156,918 1,195,242 1,224,705 1,110,941 <CURRENT-ASSETS> 4,113,266 4,326,405 4,273,851 4,226,711 <PP&E> 7,895,249 8,044,533 8,242,116 7,762,442 <DEPRECIATION> 3,621,131 3,709,198 3,839,638 3,512,904 <TOTAL-ASSETS> 9,312,020 10,553,874 10,669,342 9,412,580 <CURRENT-LIABILITIES> 3,491,495 4,526,824 4,287,888 3,790,314 <BONDS> 433,724 433,437 682,166 435,198 <PREFERRED-MANDATORY> 0 0 0 0 <PREFERRED> 0 0 0 0 <COMMON> 608,933 628,216 659,274 581,562 <OTHER-SE> 3,956,734 4,012,280 4,054,696 3,815,285 <TOTAL-LIABILITY-AND-EQUITY> 9,312,020 10,553,874 10,669,342 9,412,580 <SALES> 2,672,177 5,371,417 8,017,611 10,012,194 <TOTAL-REVENUES> 2,672,177 5,371,417 8,017,611 10,012,194 <CGS> 1,156,217 2,300,164 3,477,411 4,325,805 <TOTAL-COSTS> 1,156,217 2,300,164 3,477,411 4,325,805 <OTHER-EXPENSES> 268,616 <F1> 573,462 <F1> 852,432 <F1> 1,072,745 <F1> <LOSS-PROVISION> 13,838 4,465 23,999 32,462 <INTEREST-EXPENSE> 17,607 39,835 68,030 69,532 <INCOME-PRETAX> 681,005 1,348,272 1,945,275 2,395,319 <INCOME-TAX> 200,896 397,740 573,856 706,619 <INCOME-CONTINUING> 480,109 950,532 1,371,419 1,688,700 <DISCONTINUED> 0 0 0 0 <EXTRAORDINARY> 0 0 0 0 <CHANGES> 0 0 0 0 <NET-INCOME> 480,109 950,532 1,371,419 1,688,700 <EPS-PRIMARY> 0.61 1.21 1.75 2.12 <EPS-DILUTED> 0.60 1.20 1.73 2.10 <F30> <FN> <F1>Other expenses consist of research and development expenses </FN>